 The AdventHealth Translational Research Institute TRI in Orlando, FL to lead the study, funded by the Helmsley Charitable Trust, evaluating MBX-2982, a GPR119 agonist, for its ability to increase secretion of glucagon, a hormone that reverses low blood glucose levels hypoglycemia in individuals with type 1 diabetes T1D The AdventHealth Translational Research Institute TRI in Orlando, FL to lead the study, funded by the Helmsley Charitable Trust, evaluating MBX-2982, a GPR119 agonist, for its ability to increase secretion of glucagon, a hormone that reverses low blood glucose levels hypoglycemia in individuals with type 1 diabetes T1D 